Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes
Clinical trial approval / initiationDiabetes

Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes

Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar
BiosimilarsHuadong Medicine

Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar

CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer
CancerCSPC Pharmaceutical

CSPC Pharmaceutical’s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer

Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO
Clinical trial resultsHKG: 9688

Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO

Show More